Our most advanced asset is BEN-2293, a potent topical pan-Trk inhibitor for atopic dermatitis, which is now in a Phase Ib/IIa clinical trial. Results from the Phase Ib safety and tolerability study enabled progression to the Phase IIa study, with results expected early in 2023.
BEN-8744, our novel PDE10 inhibitor under development for ulcerative colitis, demonstrates the power of the Benevolent Platform™ to surface therapeutic targets not previously linked to a given disease. BEN-8744 was nominated as a clinical candidate only 2 years after programme initiation.
By fusing artificial and human intelligence, we empower scientists to uncover new relationships between diseases and symptoms, drugs and their effects and the subgroups of patients who will respond to treatment.